Navigation Links
Biovista Announces a Drug Repositioning Collaboration With Pfizer
Date:11/9/2010

Biovista Announces a Drug Repositioning Collaboration With Pfizer -- CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Joint Ventures Click to view news release full screen  

Biovista Announces a Drug Repositioning Collaboration With Pfizer

 

CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ -- Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista's Clinical Outcome Search Space (COSS) technology.

Under the terms of the agreement, Biovista will collaborate with Pfizer's Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates. The terms of the agreement include an upfront payment and success-based milestones.

"We seek to benefit from the collaboration with Biovista and their COSS technology to expand uses for our drugs and to help accelerate our clinical programs," said Don Frail, chief scientific officer of Pfizer's Indications Discovery Unit.

"Pfizer is an industry leader in terms of its drug repositioning efforts, supporting the vision that every drug may have potential beyond its initially developed uses," said Aris Persidis, President of Biovista. "Working with Pfizer on potential new indications may benefit expanded sets of patients with unmet medical needs, and is an opportunity to demonstrate the value of Biovista's COSS(TM) technology within the drug development workflow of bio-pharmaceutical companies," he added.

DISCLOSURE NOTICE: The information contained in this release is as of May 17, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about potential new uses for existing compounds that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications for such new uses for existing compounds that may be filed for such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential of such new uses for existing compounds; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

About Biovista:

Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own drug pipeline in multiple indications and is collaborating with the FDA on the prediction of adverse events, as well as with biopharmaceutical companies on indication expansion and de-risking of their portfolios (http://www.biovista.com).

For further information please contact: Aris Persidis Biovista, Inc. arisp@biovista.com +1-434-242-6514
'/>"/>

SOURCE Biovista
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
3. Novus Biologicals Awards Contract to Biovista Inc. to Drive its Web-Based Novus Explorer Service
4. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
5. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
6. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Anesiva Announces Second Quarter 2008 Financial Results and Update
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017  VWR Corporation (NASDAQ: VWR), the leading global independent ... customers, today reported its financial results for the fourth quarter ... 4Q16 record quarterly net sales of ... organic basis. 4Q16 EMEA-APAC segment ... while the Americas net sales increased 2.5%, or down 0.9% ...
(Date:2/23/2017)... Wisconsin (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses ... with reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency ...
(Date:2/23/2017)...  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks ... head lice treatment salon to set up shop. But there,s ... a French bistro on E Madison Ave, and CEO ... old lice clinic, we pride ourselves on being a destination ... of the stigma associated with lice. Everyone can get lice ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD ... Reception at Purdue Research Park of West Lafayette, Indiana. , The ... outstanding contributions to, and success with, commercializing discoveries from Purdue research. “This award ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
Breaking Biology News(10 mins):